国际肿瘤学杂志

国际肿瘤学杂志››2012,Vol. 39››Issue (6): 445-448.

• 综述 •上一篇下一篇

肾癌靶向治疗的常见不良反应及其治疗策略

吴小荣,刘东明

  1. 上海交通大学医学院附属仁济医院泌尿外科
  • 出版日期:2012-06-08发布日期:2012-06-25
  • 通讯作者:刘东明，E-mail: liudm541@126.com E-mail:liudm541@126.com

Toxicities of targeted therapy in renal cancer and their treatment strategies

WU Xiao-rong, LIU Dong-ming

  1. Department of Urology, Renji Hospital, Shanghai Jiaotong University Medical School, Shanghai 200001, China
  • Online:2012-06-08Published:2012-06-25
  • Contact:LIU Dong-ming, E-mail: liudm541@126.com E-mail:liudm541@126.com

PDF

1483

摘要：随着对肾癌(RCC)分子机制研究的深入，针对血管内皮生长因子（VEGF）及其受体等为靶点的肾癌靶向治疗药物取得重大进展，极大改善了进展期或转移性肾癌患者的预后。但临床试验表明，靶向治疗药物会导致高血压、骨髓抑制、肺炎等药物相关性不良反应，临床中及时发现并采取有效干预措施，对改善患者生活质量和提高靶向治疗效果尤为重要。

关键词:肾肿瘤,药物疗法,副反应

Abstract:With the indepth studies of molecular mechanisms of renal cell carcinoma (RCC), people have made great progress in the targeted therapy drugs which targeted at vascular endothelial growth factor (VEGF) and their receptors, which dramatically improve the treatment outcome for patients with advanced or metastatic RCC. However, recent clinical trails show that the targeted therapy drugs may cause adverse events, such as hypertension, bone marrow toxicity, pneumonitis and so on. It is important to manage the adverse events promptly not only to improve the therapeutic efficacy but also to improve the quality of life for patients with RCC.

Key words:Kidney neoplasms,Drug therapy,Adverse effects